

Freeport-McMoRan Higher on Tariffs; Starbucks Overseas Interest; Merck M&A
Jul 9, 2025
In a surprising twist, tariffs on copper imports cause Freeport-McMoRan's stock to soar. Starbucks is exploring significant investment proposals for its China business, hinting at a potential major deal. Meanwhile, Merck's acquisition of Verona Pharma for $10 billion aims to compensate for the expected loss of its leading cancer drug's exclusivity. In contrast, T-Mobile faces a dip after a downgrade from KeyBanc, marking a mixed day in the market.
AI Snips
Chapters
Transcript
Episode notes
Copper Tariffs Spike U.S. Prices
- President Trump's 50% tariff on copper imports caused a significant price spike in U.S. copper contracts compared to London contracts.
- This tariff divergence has increased Freeport-McMoRan's stock price and reflects shifting global copper supply dynamics.
Starbucks Eyes China Growth Potential
- Starbucks faces challenges in China due to cultural preferences but sees strong long-term potential.
- Investor interest in a controlling stake reflects efforts to grow Starbucks' presence despite slower sales.
Merck's Strategic Biotech Acquisition
- Merck's $10 billion acquisition of Verona Pharma is aimed at offsetting revenue loss from cancer drug exclusivity expiration.
- Verona Pharma's shares surged on the announcement, while Merck's shares rose modestly.